-+ 0.00%
-+ 0.00%
-+ 0.00%

SL Science notifies availability of press release on WCP 2026 glioblastoma research update

PUBT·07/17/2026 12:01:53
Listen to the news
SL Science notifies availability of press release on WCP 2026 glioblastoma research update
  • SL Science posted a press release on its WCP 2026 presentation of preclinical glioblastoma data for its gamma delta T-cell therapy platform.
  • Study results showed complete tumor elimination by day 26 at the highest dose tested, with dose-dependent efficacy on repeat dosing.
  • Safety screens reported no major adverse effects in the preclinical models.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170800PRIMZONEFULLFEED9763889) on July 17, 2026, and is solely responsible for the information contained therein.